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size. Mean size at intervention was 2.2 cm (range, 0.8-
3.7). Fifteen patients underwent open repair while 28
(including all ruptures) underwent EV embolization (n ¼
26) or covered stent exclusion (n ¼ 2). In the open surgical
cohort seven patients underwent aneurysmectomy, while
eight underwent aneurysmectomy with splenectomy. In
the elective EV cohort technical success was noted in all
patients; both patients managed for rupture required either
intra-operative or delayed conversion to splenectomy for
hemodynamic instability and splenic infarction respectively.
No major operative morbidity or mortality was identiﬁed
following elective open or EV repair. No recurrence, aneu-
rysm-related mortality or major morbidity was identiﬁed
during a mean follow-up of 42 months (range, 0-89).
Conclusions: This contemporary experience is com-
parable to our historical experience in female predomi-
nance, aneurysm size at intervention, and postoperative
morbidity and mortality justifying the current EV
approach. There has been a reduction in grand multiparity
by half (25% to 13%). Rupture remains a recognized risk
which carries notable morbidity and mortality.
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Stenosis
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Objectives: The endovascular management of athero-
sclerotic renal artery stenosis (RAS) has evolved over
several decades. Endovascular therapy with stents (PTAS)
often utilizes balloon-expandable bare-metal stents due to
their radial force. However, restenosis frequently occurs.
No studies have investigated the patency of covered stents
in comparison to bare-metal stents in the treatment of
RAS.
Methods: We performed a retrospective chart review
of 197 patients at our institution who underwent renal
artery stenting for atherosclerotic RAS from 2005-2011.
179 patients were included with a total of 206 stented renal
arteries and 226 PTAS interventions. Index cases as well as
ﬁrst and second reinterventions were examined.
Results: 179 patients were included in the study with
a total of 226 interventions performed with PTAS. Of these
interventions, 195 were index (ﬁrst) procedures. 20 PTAS
were in vessels which had required one previous interven-
tion and 11 PTAS were in vessels that required two
previous interventions. The average follow-up was 30
months. 48 vessels were treated with angioplasty and
covered stents and 178 vessels were treated with angio-
plasty and bare-metal stents. 4 of 48 (8.3%) in the covered
stent group and 41 vessels of 178 (23%) in the bare-metalstent group developed restenosis requiring intervention.
Primary patency for covered stents was 100% at 12 months
and 93% at 24 months; bare metal stent patency was 83% at
12 months and 74% at 24 months. There was a statistical
signiﬁcance in patency in comparing covered stents to
bare-metal stents with P < .045 in the overall study.
Conclusions: While initial success was seen in treat-
ing RAS with bare-metal stents, covered stents confer
increased primary patency and decreased need for repeat
secondary interventions. Covered stents should be
considered in renal artery stenting for both primary index
procedures and secondary interventions due to their
improved performance over bare-metal stenting for ostial
RAS.
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Objectives: Carotid interventions have been shown to
decrease stroke risk and improve cerebral perfusion.
However, nearly 40% of patients who undergo carotid
revascularization procedures experience cognitive deterio-
ration. We have demonstrated that subclinical microembo-
lization is associated with memory decline. The role of
genetic factors in cognitive function is unclear. We herein
seek to assess genetic determinants as potential risk factors
for these procedures.
Methods: Over one year period, patients undergoing
carotid interventions at a single academic institution were
recruited to participate. Patients underwent neuropsycho-
logical testing two weeks prior to and at one month
following their procedure and MRI prior to and within
48 hours following their procedure. Saliva samples were
collected for genetic testing and demographics were
recorded. Logistic regressions were used to search for
associations.
Results: 34 patients were included (18 CAS, 16
CEA); all were male with a mean age of 68. The majority
of patients exhibit hypertension (94%) and have a history
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(47%), obesity (35%), and CAD (44%). Consistent with
previous ﬁndings, CAS was associated with higher inci-
dence of microemboli (P ¼ .0005) and with susceptibility
to memory decline (P ¼ .0085). Negative univariate asso-
ciations were found for 5-HTT (serotonin transporter)
short alleles with memory decline (P ¼ .016) and brain-
derived neurotrophic factor (BDNF) polymorphism with
incidence of microemboli (P ¼ .018). After adjusting for
ApoE risk alleles, incidence of microemboli trended with
memory decline (P ¼ .099).
Conclusions: Despite a small number of patients, our
study showed that genetic polymorphisms such as 5-HTT,
BDNF, and ApoE may provide additional insight on post-
operative changes in cognition. Further investigation of
these polymorphisms is warranted to understand and
potentially prevent cognitive deterioration following
carotid revascularization procedures.
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Symptom Status and Degree of Ipsilateral Stenosis
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Objectives: The impact of degree of contralateral
stenosis on outcome after CAS and CEA remains
unknown. We aimed to identify those patients at increased
procedural risk due to contralateral stenosis or occlusion
(CO).
Methods: All patients undergoing CEA or CAS in
the Vascular Study Group of New England were identi-
ﬁed from 2003-2011. Patients were stratiﬁed by
symptom status and degree of ipsilateral stenosis. Primary
endpoint was any stroke or death (S/D) at 30 days.
Bivariate and multivariable analyses (adjusted for age,Table. Thirty-day stroke/death rate in symptomatic and asym
CS < 50% CS 50-79%
No. % No. %
ASX
Ipsi 50-80% (n ¼ 1655) 9 0.9 3 0.6
Ipsi >80% (n ¼ 4945) 18 0.7 14 0.9
SX
Ipsi 50-80% (n ¼ 1115) 10 1.4 7 2.4
Ipsi >80% (n ¼ 2195) 25 2.1 11 1.7
ASX, Asymptomatic; CO, contralateral occlusion; CS, contralateral stenosis; ISPgender and procedure) were done to assess the impact
of the degree of contralateral stenosis as assessed by
Duplex Ultrasound.
Results: 9362 CEA patients (33.4% symptomatic
[sx]) and 663 CAS patients (34.4% sx) were included.
Contralateral disease did not impact outcome in asymp-
tomatic (asx) patients with 50-80% ipsilateral stenosis.
Asx patients with ipsilateral >80% stenosis and CO had
signiﬁcantly increased S/D rate (3.4%; P < .01; OR, 5.4
[2.6-11.4]). Sx patients with >80% ipsilateral stenosis
were not impacted by contralateral stenosis, while those
with 50-80% ipsilateral stenosis and 80-99% contralateral
stenosis had the highest S/D rate (6.9%; P ¼ .05; OR,
5.1 [1.1-24.7]).
Conclusions: The impact of contralateral disease on
outcome after carotid revascularization is different for asx
vs sx patients. Regardless of procedure, CO increases the
risk for asx patients with >80% ipsilateral stenosis, while
80-99% contralateral stenosis increases the risk for sx
patients with 50-80% ipsilateral stenosis.
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Objectives: Postoperative readmission is associated
with increased morbidity and mortality. We evaluated risk
factors for readmission and postdischarge mortality
following carotid endarterectomy (CEA) in the ACS-
NSQIP.
Methods: All patients undergoing CEA without
concurrent cardiac procedure in the 2011 NSQIP were
identiﬁed. Independent predictors of 30-day readmission
and postdischarge mortality were determined using multi-
variable logistic regression.ptomatic undergoing CEA or CAS
CS 80-99% CO
P value
Total
No. % No. % No. %
0 0 1 0.9 .88 13 0.8
1 0.3 12 3.4 <.001 45 0.9
2 6.9 3 5.1 .05 22 2.0
6 3.5 2 1.7 .56 44 2.1
I, ipsilateral; SX, symptomatic.
